Screener
Discontinued — last reported Q2 '25
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Pulse Biosciences, Inc.’s 10-Q, filed August 12, 2025.
- Filed
- Aug 12, 2025
- Fiscal quarter
- Q2 FY2025
- Calendar quarter
- Q2 2025
- Accession
- 0001437749-25-026209
| Revenues: / Product revenues / Total revenues | Three Months Ended June 30, 2025 / — | Three Months Ended June 30, 2024 / — | Six Months Ended June 30, 2025 / — | Six Months Ended June 30, 2024 / — |
|---|---|---|---|---|
| Cost and expenses: | ||||
| Research and development | 12,088 | 7,230 | 22,401 | 13,971 |
| General and administrative | 8,187 | 4,496 | 15,918 | 8,370 |
| Total cost and expenses | 20,275 | 11,726 | 38,319 | 22,341 |
| Loss from operations | (20,275) | (11,726) | (38,319) | (22,341) |
| Other income: | ||||
| Interest income, net | 1,107 | 343 | 2,356 | 821 |
| Total other income | 1,107 | 343 | 2,356 | 821 |
Document
FAQ
- What is Pulse Biosciences, Inc.'s G&A?
- Pulse Biosciences, Inc. (PLSE) reported G&A of $8.19M in Q2 2025.
- How has Pulse Biosciences, Inc.'s G&A changed year-over-year?
- Pulse Biosciences, Inc.'s G&A increased by 82.1% year-over-year, from $4.5M to $8.19M.
- What is the long-term trend for Pulse Biosciences, Inc.'s G&A?
- Over 3 years (2021 to 2024), Pulse Biosciences, Inc.'s G&A has grown at a 7.8% compound annual growth rate (CAGR), from $19.07M to $23.92M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Pulse Biosciences, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude